VELGRAFT for Diabetic Foot Ulcers

This trial tests a new treatment called VELGRAFT for individuals with diabetic foot ulcers unresponsive to standard care. Researchers aim to determine if VELGRAFT is safe and more effective in healing these wounds compared to usual treatments. Participants must have diabetes and a foot ulcer present for more than 4 weeks but less than 24 weeks, with some healing tissue visible. Good blood flow to the affected foot and willingness to wear special footwear to aid healing are also required. As a Phase 1 trial, participants will be among the first to receive this treatment, helping researchers understand its effects in people.

The trial does not specify if you need to stop taking your current medications. However, if you are on chemotherapeutic agents, immunosuppressive agents, radiation therapy, or corticosteroids, you cannot participate if you've received treatment within one month prior to the trial.

Research has shown that VELGRAFT, a new treatment for diabetic foot ulcers, is in the early testing stages. The current focus is to ensure its safety for use. As a Phase 1 trial, the primary goal is to identify any side effects and assess patient tolerance. Detailed safety data is limited at this stage, but Phase 1 trials primarily address safety, and any serious issues would likely halt further testing.

VELGRAFT resembles other skin substitute treatments for diabetic foot ulcers, which have generally been well-tolerated. Research has found that biologically based treatments, like VELGRAFT, can improve healing outcomes. While this suggests potential benefits, further research is necessary to confirm its safety.

Unlike the standard care for diabetic foot ulcers, which often involves wound cleaning, dressing, and infection management, VELGRAFT offers a unique approach. VELGRAFT is a bioengineered skin substitute designed to promote faster healing by mimicking natural skin structures. This innovative treatment holds promise because it could potentially reduce healing time and improve the quality of new tissue. Researchers are particularly excited about VELGRAFT's ability to integrate with the patient's own skin, offering a more seamless and effective healing process compared to traditional methods.

Research has shown that VELGRAFT, which participants in this trial may receive, may help heal diabetic foot ulcers. In a recent study, 75% of wounds treated with VELGRAFT completely healed after 12 weeks, indicating its potential effectiveness. This trial will compare VELGRAFT to standard care, the treatment received by the control group. A review of similar treatments found they healed better than standard care. These findings are promising for those considering participation in this trial using VELGRAFT for diabetic foot ulcers.¹³⁴⁶⁷